Subject Insights to Understand Rheumatoid Arthritis (RA)

NCT03285191 | Completed

• 1 other identifier: 206577
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting the joints and can lead to joint pain, swelling, redness and stiffness and can cause deformity, loss of strength and immobility. This cross-sectional qualitative study aims to explore the burden of established RA by conducting semi-structured Concept elicitation (CE) interviews (60 minutes duration) and real-time data capture task. The conceptual model developed from this data will be used to support the development of GSK3196165, a recombinant human monoclonal antibody (mAb) targeted for the treatment of RA. The CE interviews will explore the subject experience of RA and will collect information about symptoms, disease impact on functioning and health related quality of life (HRQoL), and treatment experiences/impacts of the condition and the language used by subjects to describe them. Following the CE interview, subjects will be asked to complete a brief symptom ranking exercise where they will need to rank how bothersome each RA symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS). After the interviews, the real-time disease experience of subjects will be captured by the real-time data capture app-based activity over a period of 7 days. Approximately 30 English-speaking subjects from the United States (US) with RA who are inadequate responders of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and/or (bDMARDs) will participate in the interviews and of these, 10 subjects will be offered the opportunity to participate in the real-time data capture sub study.

Conditions

Arthritis, Rheumatoid

Keywords

NRS; Concept elicitation; Real-time data capture; Rheumatoid arthritis; GSK3196165

Outcome Measures

Primary Outcomes (1)

• Number of subjects with RA participating in CE interviews

  CE interviews will be carried out to explore disease experience with respect to symptoms, impacts and treatment/surgical experiences.

  1 day

Secondary Outcomes (2)

• Analysis of RA experience by using real-time data data capture task

  Up to 7 days

• Preparation of the conceptual model

  Up to 7 days

Study Arms (2)

Subjects participating in the CE interview

Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.

Other: Numerical rating scale

Subjects participating in interview and real-time data capture

Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.

Other: Numerical rating scale; Other: Real-time data capture app

Interventions

Numerical rating scale OTHER

Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).

Subjects participating in interview and real-time data capture; Subjects participating in the CE interview

Real-time data capture app OTHER

Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.

Subjects participating in interview and real-time data capture

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Thirty English speaking subjects from the US with RA who are inadequate responders to csDMARDs and/or bDMARDs will be included in this study.

You may qualify if:

• Male or female, aged \>=18 years or over.
• Subject has a diagnosis of rheumatoid arthritis and has had this diagnosis for at least 6 months.
• Subject has a minimum of four swollen and tender joints.
• Subject is either an inadequate responder to csDMARDs and has never received a bDMARD or an inadequate responder to bDMARDs (subject may be receiving bDMARDs only or may be continuing csDMARD treatment in addition to receiving a bDMARD).
• Subject is willing and able to participate in the study and provide written informed consent.
• Subject is a fluent US-English speaker and is able to read, write and fully understand the US-English language.
• Subject is willing and able to participate in a 60-minute interview and optional app task to discuss their experience of rheumatoid arthritis.
• For subjects taking part in real-time data capture:
• Subject owns/or has access to either a smartphone \[iPhone Operating System (iOS) or android\] or tablet which has video, audio/microphone and photographic capabilities and access to either the Apple app store or Google play store to download the app.
• Subject is willing and able to take part in the real time data application task and respond to a series of questions/tasks fielded via the application over the course of seven days and is willing to respond to some brief questions following the real-time data capture task about their experience of using the app and completing the tasks, in a 5-10 minute telephone call.
• Subject would feel comfortable recording short videos of themselves and providing audio commentary in response to app questions/tasks.

You may not qualify if:

• Subject has a history of other inflammatory rheumatological or autoimmune disorders that are not secondary to RA.
• Subject has significant unstable or uncontrolled acute or chronic disease other than RA.
• Subject is unwilling or unable to comply with the requirements of the study or has a physical or mental condition that, in the opinion of the physician, may affect the subject's ability to participate in the study, the responses he/she might provide or their ability to provide consent.
• Subject is currently or has previously been enrolled in a clinical trial for RA in the past year.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Bollington, Cheshire, SK10 5JB, United Kingdom

Location

Related Links

• Results for study 206577 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 29, 2017
• First Posted: September 15, 2017
• Study Start: July 3, 2017
• Primary Completion: August 17, 2017
• Study Completion: August 17, 2017
• Last Updated: August 15, 2018

Record last verified: 2018-08

Locations

GB (1)